Universe Pharmaceuticals INC (UPC) News
Filter UPC News Items
UPC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest UPC News From Around the Web
Below are the latest news stories about UNIVERSE PHARMACEUTICALS INC that investors may wish to consider to help them evaluate UPC as an investment opportunity.
Univest Securities, LLC Announces Closing of $15 Million Registered Direct Offering for its Client Universe Pharmaceuticals INC (NASDAQ: UPC)New York, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the “Offering”) of its client Universe Pharmaceuticals INC (NASDAQ: UPC) (the “Company”), a pharmaceutical producer and distributor in China. Under the terms of the securities purchase agreement, the Company has agreed to sell to several instit |
Universe Pharmaceuticals INC Announces $15 Million Registered Direct OfferingJiangxi, China, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (Nasdaq: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 18,750,000 of the Company’s ordinary share, par value $0.28125 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $0.80 per share in a regi |
Universe Pharmaceuticals INC Announces Share ConsolidationJiangxi, China, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 15 ordinary shares with par value of US$0.01875 per share each in the Company’s issued and unissued share capital into one (1) ordinary share with par value of US$0.28125 (the “Share Consolidation”). As a result of the Share Consolida |
Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJi’an, Jiangxi, China, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on October 25, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq. Nasdaq L |
Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024JI’AN, Jiangxi, China, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company,” “we,” “our” and “us”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its unaudited financial results for the first six months of fiscal year 2024 ended March 31, 2024. Mr. Gang Lai, Chairman of the Board of Directors and CEO of Universe Pharmaceuticals INC, commented, “During the first six months of fiscal year 2024, we navigated business uncertainties and ad |
Fall Trends in Shareholder Activism: Vinson & Elkins Partner Patrick Gadson, Live from NYSECorpGov hosted a fireside chat on Sept. 13 from the floor of the New York Stock Exchange with Patrick Gadson, Partner at Vinson & Elkins. Mr. Gadson spoke to Editor-in-Chief John Jannarone about the top trends to watch in shareholder activism this fall, interest rate cuts and the resulting decline in financing costs with the possible […] The post Fall Trends in Shareholder Activism: Vinson & Elkins Partner Patrick Gadson, Live from NYSE appeared first on CorpGov. |
Universe Pharmaceuticals INC Reports Fiscal Year 2023 Financial ResultsUniverse Pharmaceuticals INC ("Universe Pharmaceuticals" or the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its financial results for the fiscal year ended September 30, 2023. |